# EUR-Lex - 52013PC0498 - EN

*|*

# 52013PC0498

**Proposal for a DECISION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme jointly undertaken by several Member States /* COM/2013/0498 final - 2013/0243 (COD) */**

			*

			*

EXPLANATORY MEMORANDUM

1.           CONTEXT OF THE PROPOSAL

The European and Developing Countries
Clinical Trials Partnership (EDCTP) was established in 2003 in response to the
global health crisis caused by the three main poverty-related diseases —
HIV/AIDS, malaria and tuberculosis — and to the EU’s commitment to achieving
the United Nation’s Millennium Development Goals by 2015. The first EDCTP
programme (EDCTP1, 2003-2012) is now beyond its active funding period.

Despite the results and impact of EDCTP so
far, the health and socio-economic burden of poverty-related diseases persists
and hinders the sustainable development of developing countries, in particular
in sub-Saharan Africa. More than one billion people, including 400 million
children, are suffering from one or more poverty-related diseases, including
neglected infectious diseases such as sleeping sickness and worm infections.
HIV/AIDS alone kills an estimated 2 million people, while malaria and
tuberculosis together kill an estimated 2.2 million people annually. In
addition to creating unnecessary suffering and premature deaths these diseases
undermine productivity and increase insecurity and infirmity, thus perpetuating
the cycle of poverty. Sub-Saharan Africa is disproportionately affected by such
diseases, with approximately 90 % of all malaria-related deaths occurring
in Africa. This region also accounts for over two thirds of all people living
with HIV and for nearly three quarters of AIDS-related deaths.

While general improvements in nutrition,
sanitation and health infrastructure are important, the effective long-term
control of poverty-related diseases also requires the development of new or
improved medical interventions (products, treatments and vaccines). While there
is a general lack of such medical products, many of the existing drugs and
vaccines currently used date back to the early 20th century and, moreover, are
no longer effective due to the emergence of drug resistance in these diseases.
Most of the new drugs and vaccines under development, however, are stuck at the
stage of early clinical development. This is mainly due to the significant
costs involved in the clinical development and testing needed in humans to
prove the effectiveness and safety of new or improved medical interventions. These
costs are linked to three key problem drivers: (i) insufficient investment by
the private sector due to a lack of return on investment (market failures),
(ii) weak clinical research capacity in sub-Saharan African countries, and
(iii) fragmented public support.

Following the recommendations from the
independent interim evaluation of EDCTP1 and the conclusions from the Member
States’ meeting in September 2010, the Belgian EU Council Presidency proposed
to the Competitiveness Council on 26 November 2010 the launch of a second EDCTP
joint programme (EDCTP2) with at least ten years duration. To that end, the
EDCTP1 participating states published a Strategic Business Plan 2014-2024 for
EDCTP2.

On these grounds, the Commission puts
forward a proposal for a Decision on the participation of the EU in a second
European and Developing Countries Clinical Trials Partnership Programme
(EDCTP2) based on Article 185 of the Treaty on the Functioning of the EU, which
makes provision for the EU to participate in research and development
programmes undertaken by several Member States.

Aim of EDCTP2

The general objective of EDCTP2 is to
improve the EU'’s capacity to invest more efficiently in the research and
development of new or improved medical interventions against poverty-related
diseases for the benefit of and in partnership with developing countries, in
particular sub-Saharan African countries.

More specifically, EDCTP2 aims to achieve
the following specific objectives:

·
An increased number of new or improved medical interventions
for HIV/AIDS, tuberculosis, malaria and other poverty-related diseases, and by
the end of the programme to have delivered at least one new medical
intervention, such as a new drug or a new vaccine against TB or any other
poverty-related disease; to have issued at least 30 guidelines for improved or
extended use of existing medical interventions; and to have progressed the
clinical development of at least 20 candidate medical interventions.

·
Strengthened cooperation with sub-Saharan
African countries, in particular on building their capacity for conducting
clinical trials in full compliance with fundamental ethical principles and
relevant national, Union and international legislation, including the EU’s
Charter of Fundamental Rights, the European Convention on Human Rights and its
Supplementary Protocols, the 2008 version of the World Medical Association’s
Declaration of Helsinki and the standards on good clinical practice of the
International Conference on Harmonisation.

·
Better coordination, alignment and integration
of relevant national programmes to increase the cost-effectiveness of European
public investments.

·
Extended international cooperation with
other public and private funders.

·
An increased impact due to effective cooperation
with relevant EU initiatives, including EU development assistance.

EDCTP2 has been conceived to complement the
actions implemented under the European Development Funds and the Development
Cooperation Instruments, and to respond to the Union’s commitment to the 2012 Rio+20 conference conclusions on developing and achieving internationally agreed
Sustainable Development Goals, following and including the Millennium
Development Goals.

2.           RESULTS OF CONSULTATIONS WITH THE
INTERESTED PARTIES AND IMPACT ASSESSMENTS

The preparation of the proposal has taken
full account of the responses received to an extensive stakeholder
consultation, including a public consultation. Views were expressed by European
and African policy makers as well as stakeholders from industry, academia and
civil society. The proposal also relies on the external interim evaluations of
the EDCTP1 programme and the in-depth impact assessment of the prospective
EDCTP2 programme. These consultations, evaluations and assessments of the EDCTP
consistently call for it to be continued but with the next programme lasting 10
years and covering a scope that extends to other poverty-related diseases
(beyond HIV/AIDS, tuberculosis and malaria) and to all phases of clinical
development. The geographical focus should continue to be on sub-Saharan
Africa, which is disproportionally affected by poverty-related diseases and
with which the Union has established a strategic partnership.

3.           LEGAL ELEMENTS OF THE PROPOSAL

3.1 Legal basis

The proposal for the EDCTP2 Programme is
based on Article 185 of the Treaty on the Functioning of the EU, which allows
the Union, in implementing the multiannual framework
programme, to make provision, for participation in research and development
programmes undertaken by several Member States, in agreement with the Member
States concerned, including participation in the structures created for the
execution of those programmes.

3.2 Subsidiarity principle

The fundamental basis of the EDCTP
initiative is the joint programme being based on and composed of national
programmes and activities of the participating Member States and Associated
Countries, with the support and participation of the Union.

It improves cost-effectiveness of Europe’s
investment in clinical research programmes by providing a common platform that
can better exploit research results for the development of new or improved
medical interventions against HIV/AIDS, malaria, tuberculosis and other
poverty-related diseases for the benefit of the developing countries, in
particular in sub-Saharan Africa. The expected impact at the European level
will be greater than the sum of the impacts of national programmes and
activities. It will allow the required critical mass to be achieved, both in
human and financial terms, by bringing together available complementary
expertise and resources to accelerate the development of new or improved
medical interventions that are urgently needed to reduce the devastating impact
of poverty-related diseases in developing countries. Furthermore, at the global
level it contributes to a unified voice to represent European research efforts
in the fight against these diseases in developing countries. Finally, it
promotes a long-term structuring effect on European and developing countries’
research policies and systems alike, and helps to integrate the EU’s research
and development policies and systems in a coherent context.

The Commission’s proposal for Horizon 2020
makes provision for the Union’s continued participation in a second EDCTP
programme under Article 185 of the Treaty, which is the appropriate instrument
for the Union to support the EDCTP since it allows for both the coordination of
national research programmes and the participation of the Union in the joint
programme.

3.3 Proportionality principle

The proposal
does not go beyond what is necessary to achieve its objectives. Union
participation in the EDCTP2 Programme will take place within the limits of the
competence provided by the Treaty and will only facilitate and support,
including financially, the fulfilment of the EDCTP2 objectives by the
participating states. They will have to collaborate and work towards reaching better coordination, alignment and integration of relevant national
programmes or activities and ultimately developing more and better
medical interventions against HIV/AIDS, tuberculosis, malaria, as well as other
poverty related diseases.

4.           BUDGETARY IMPLICATION

The Legislative Financial Statement
presented with this decision sets out the indicative budgetary implications.
The Union contribution shall be up to EUR 683 million[1] including EFTA contribution.
The envelope is in current prices. The Union contribution shall be made from
the ‘Health, demographic change and wellbeing’ challenge, DG Research &
Innovation envelope, as part of the implementation of Horizon 2020 – The
Framework Programme for Research and Innovation. The maximum amount of Union
contribution for administrative costs is up to EUR 41 million.

During the course of the action, the Union
may consider matching additional commitments from Participating Member States or countries associated to Horizon 2020 Framework
Programme.

2013/0243 (COD)

Proposal for a

DECISION OF THE EUROPEAN PARLIAMENT
AND OF THE COUNCIL

on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme
jointly undertaken by several Member States

(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE
COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the
Functioning of the European Union, and in particular Articles 185 and the
second paragraph of Article 188 thereof,

Having regard to the proposal from the
European Commission,

After transmission of the draft legislative
act to the national Parliaments,

Having regard to the opinion of the European
Economic and Social Committee[2],

Acting in accordance with the ordinary
legislative procedure,

Whereas:

(1)
In its Communication Europe 2020 A Strategy for
smart, sustainable and inclusive growth[3],
the Commission underscores the need to develop favourable conditions for
investment in knowledge and innovation so as to achieve smart, sustainable and
inclusive growth in the Union. The European Parliament and Council have
endorsed this strategy.

(2)
Horizon 2020 — The Framework Programme for
Research and Innovation (2014-2020) established by Regulation (EU) No .../2013 of
the European Parliament and of the Council of ... 2013[4] (hereinafter “Horizon 2020
Framework Programme”) aims at achieving a greater impact on research and
innovation by contributing to the strengthening of public-public partnerships,
including through Union participation in programmes undertaken by several
Member States in accordance with Article 185 of the Treaty.

(3)
By Decision No 1209/2003/EC of the European
Parliament and of the Council of 16 June 2003 on Community participation in a
research and development programme aimed at developing new clinical
interventions to combat HIV/AIDS, malaria and tuberculosis through a long-term
partnership between Europe and developing countries, undertaken by several Member
States[5],
the Community decided to make a financial contribution to the European and
Developing Countries Clinical Trials Partnership (hereinafter ''EDCTP1'')
matching that of the participating states but not exceeding EUR 200 million,
for the duration of the Sixth Framework Programme of the European Community for
research, technological development and demonstration activities, contributing
to the creation of the European Research Area and to innovation (2002 to 2006)
established by Decision No 1513/2002/EC of the European Parliament and of the
Council of 27 June 2002[6].
EDCTP1 was also supported under the Seventh Framework Programme of the European
Community for research, technological development and demonstration activities
(2007 – 2013) established by Decision No 1982/2006/EC of the European
Parliament and of the Council of 18 December 2006[7].

(4)
In 2009, independent
experts adopted the report of the interim evaluation of EDCTP1[8]. The opinion of the expert
panel was that EDCTP1 provided a unique platform for a genuine dialogue with
African scientists and it has started to bridge the gap between North and South
in building research capacities and in providing learning and working
opportunities for young African researchers. Following this report, there are
fundamental issues to be taken into consideration for a second European and
Developing Countries Clinical Trials Partnership Programme (hereinafter
''EDCTP2 Programme''): the current scope of EDCTP1 needs to be changed and
extended; the integration of European national programmes should be further
improved; collaboration with other major public and private funders, including
the pharmaceutical industry, needs to be strengthened and extended; synergies
with European external policy actions should be developed, in particular with Union
development assistance; co-funding rules should be clarified and simplified;
monitoring tools need to be strengthened.

(5)
According to Council Decision ... /2013/EU of ...
2013 establishing the Specific Programme implementing Horizon 2020 - The
Framework Programme for Research and Innovation (2014-2020)[9] further support may be provided
to the EDCTP2 Programme.

(6)
EDCTP1 had major achievements and has so far
developed eight improved medical treatments, in particular for new-borns,
children or pregnant/lactating women suffering from HIV/AIDS or malaria. It has
resulted in the launch of the first four African Regional Networks of
Excellence promoting South-South cooperation on clinical research and more than
400 African researchers have been trained. It has also contributed to establishing
the Pan-African Clinical Trials Registry and the African Vaccine Regulators
Forum.

(7)
Despite the considerable results and
achievements of EDCTP1, poverty-related diseases still represent a major obstacle
to the sustainable development of developing countries due to their social and
economic burden, especially in sub-Saharan Africa. Effective, safe and
affordable medical treatments still do not exist for most poverty-related
diseases and investment in clinical research remains inadequate as conducting
clinical trials is costly and the return on investment is limited due to market
failure. Moreover, European research activities and programmes are still often
fragmented and thus either subcritical in scale or overlapping, whereas
research capacity and investment in developing countries are inadequate.

(8)
The European Parliament adopted a resolution on
15 June 2010 on progress towards achieving the Millennium Development Goals
(hereinafter ''MDG'') ahead of the UN high-level meeting in September 2010 in
which it ‘asks the Commission, the Member States and developing countries to
address MDG 5 (on improving maternal health), MDG 4 (on child mortality) and
MDG 6 (on HIV/AIDS, malaria and tuberculosis) in a coherent and holistic way’.

(9)
The Union is committed to the 2012 Rio+20
conference conclusions on developing and achieving internationally agreed
Sustainable Development Goals (hereinafter ‘‘SDG’), following and including the
MDG.

(10)
In 2000 the Union launched a high-level policy
dialogue with Africa leading to the establishment of an Africa-EU Strategic
Partnership, following which a Joint Africa-EU Strategy was adopted in 2007 and
a high-level policy dialogue on Science, Technology and Innovation was established
in 2011.

(11)
The Commission presented a communication on 31
March 2010 on the Union’s role in global health[10] which calls for a more
coordinated approach among Member States and across relevant policies to
identify and jointly address shared global priorities for health research.

(12)
The Commission presented a communication on 21
September 2011 on partnering in research and innovation[11] which puts partnerships across
institutional, national and continental borders at the centre of the Union’s research policy.

(13)
In line with the objectives of Horizon 2020
Framework Programme, any Member State and any country associated to the Horizon
2020 Framework Programme should be entitled to participate in the EDCTP2
Programme.

(14)
The participating states intend to contribute to
the implementation of EDCTP2 Programme during the period covered by the EDCTP2
Programme (2014 – 2024).

(15)
A ceiling should be established for the Union's participation in EDCTP2 for the duration of Horizon 2020 Framework Programme. Within
that ceiling, the Union contribution should be equal to the initial contributions
committed by the participating states in order to achieve a high leverage
effect and ensure a stronger integration of participating states' programmes. That
ceiling should also provide for matching the contributions from any other Member State or country associated to Horizon 2020 Framework Programme joining the EDCTP2
Programme during the Horizon 2020 Framework Programme.

(16)
The Union’s financial contribution should be
subject to formal commitments from the participating states to contribute to
implement the EDCTP2 Programme and their fulfilment.

(17)
The joint implementation of the EDCTP2 Programme
requires an implementation structure. The participating states have agreed on the
implementation structure for EDCTP2 and set up the EDCTP2-Implementation
Structure (hereinafter ‘‘EDCTP2-IS’’). The EDCTP2-IS should be the recipient of
the Union’s financial contribution and should ensure efficient implementation
of the EDCTP2 Programme.

(18)
The Union’s financial contribution should be
managed in compliance with the principle of sound financial management and in
accordance with the relevant rules on indirect management set out in Regulation
(EU, Euratom) No 966/2012 of the European Parliament and the Council of 25
October 2012 on the financial rules applicable to the general budget of the
Union[12]
and Commission Delegated Regulation (EU) No 1268/2012 of 29 October 2012 on the
rules of application of Regulation (EU, Euratom) No 966/2012[13].

(19)
In order to protect the Union’s financial
interests, the Commission should have the right to reduce, suspend or terminate
the Union’s financial contribution if the EDCTP2 Programme is implemented
inadequately, partially or late, or if the participating states do not
contribute, or contribute partially or late, to the financing of the EDCTP2
Programme. Those rights should be provided for in the delegation agreement to
be concluded between the Union and the EDCTP2-IS.

(20)
In order to efficiently implement the EDCTP2
Programme, financial support should be provided by the EDCTP2-IS mainly in the
form of grants to participants in actions selected at the level of the
EDCTP2-IS. The selection of these actions should be made following open and
competitive calls for proposals under the responsibility of the EDCTP2-IS.

(21)
Participation in indirect actions under the
EDCTP2 Programme is subject to Regulation (EU) No .../2013 of the European
Parliament and of the Council of ... 2013 laying down the rules for the
participation and dissemination in Horizon 2020 Framework Programme for
Research and Innovation (2014-2020)[14].
However, due to specific operating needs of the EDCTP2 Programme it is
necessary to provide for derogations from that Regulation in accordance with
Article 1(3) of that Regulation.

(22)
Derogations from Articles 8(1)(b), 9(1)(c) and
11 of Regulation (EU) No .../2013 are necessary in order to require participation
and allow funding of African entities, and allow cooperation through joint
calls between the EDCTP2 Programme and any other legal entity.

(23)
Audits of recipients of Union funds provided in
accordance with this Decision should ensure a reduction of administrative
burden, in compliance with the Horizon 2020 Framework Programme.

(24)
The Union’s financial interests should be
protected through proportionate measures throughout the expenditure life-cycle,
including the prevention, detection and investigation of irregularities, the
recovery of funds lost, wrongly paid or incorrectly used and, where
appropriate, administrative and financial penalties in accordance with
Regulation (EU, Euratom) No 966/2012.

(25)
The Commission should conduct interim evaluations,
assessing in particular the quality and efficiency of EDCTP2, progress towards
the objectives set and a final evaluation and prepare reports on those
evaluations.

(26)
Upon request from the Commission, EDCTP2-IS and
the participating states should submit any information the Commission needs to
include in the reports on the evaluation of the EDCTP2 Programme.

(27)
It is essential that the research activities
carried out under the EDCTP2 Programme are in full compliance with the Charter
of Fundamental Rights of the European Union, the European Convention on Human
Rights and its Supplementary Protocols, ethical principles included in the World
Medical Association's Declaration of Helsinki of 2008, the standards of good
clinical practice adopted by the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use, relevant
EU legislation and local ethics requirements of the countries where the
research activities are to be conducted.

(28)
Since the objectives of this Decision, namely to
contribute to the reduction of the social and economic burden of
poverty-related diseases in developing countries and in particular in
sub-Saharan Africa by accelerating the clinical development of effective, safe
and affordable medical interventions for poverty-related diseases, cannot be
sufficiently achieved by the Member States due to the lack of necessary
critical mass to be achieved, both in human and financial terms, and can
therefore, by reason of the scale of the action, be better achieved at Union
level, the Union may adopt measures, in accordance with the principle of
subsidiarity as set out in Article 5 of the Treaty on the European Union. In
accordance with the principle of proportionality, as set out in that Article, this
Decision does not go beyond what is necessary for that purpose.

HAVE ADOPTED THIS DECISION:

Article 1

Participation
in the second European and Developing Countries Clinical Trials Partnership Programme

1.           The Union shall
participate in the second European and Developing Countries Clinical Trials
Partnership Programme (hereinafter ‘the EDCTP2 Programme’), jointly undertaken
by Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy,
Luxembourg, the Netherlands, Austria, Portugal, Sweden, and the United Kingdom as
well as Switzerland and Norway (hereinafter ''participating states'') in
accordance with the conditions set out in this Decision.

2.           Any other Member State and any other country associated to the Horizon 2020 – The Framework Programme
for Research and Innovation (2014 – 2020) established by Regulation (EU) No
.../2013... (hereinafter “Horizon 2020 Framework Programme“) may participate in the
EDCTP2 Programme provided it fulfils the criterion set out in Article 3(1)(e)
of this Decision. Those Member States and countries associated to the Horizon
2020 Framework Programme that fulfil the condition set out in Article 3(1)(e) shall
be regarded as ‘participating states’ for the purposes of this Decision.

Article 2

Union's
financial contribution

1.           The maximum Union financial
contribution, including EFTA appropriations, to the EDCTP2 Programme shall be
EUR 683 million, as follows:

(a)
EUR 594 million to equal the contributions of participating
states listed in article 1.1;

(b)
EUR 89 million to equal the contributions of any
other Member State or any other country associated to Horizon 2020 Framework
Programme participating in the EDCTP2 Programme in accordance with Article 1.2.

2.           The contribution shall be
paid from the appropriations in the general budget of the Union allocated to
the relevant parts of the Specific Programme implementing Horizon 2020
Framework Programme, established by Decision ... /2013/EU in accordance with
Article 58(1)(c)(vi) and Articles 60 and 61 of Regulation (EU, Euratom) No
966/2012.

3.           Up to 6% of the Union’s financial contribution may be used by the implementing structure of EDCTP2
(hereinafter ''EDCTP2-IS'') to cover its administrative costs.

Article 3

Conditions
for the Union’s financial contribution

1.           The Union’s financial
contribution shall be conditional upon the following:

(a)
the demonstration by the participating states
that the EDCTP2 Programme is set up in accordance with Annexes I, II and III to
this Decision;

(b)
the designation by the participating states or
organisations designated by the participating states of the EDCTP2-IS, an
entity with legal personality as the structure responsible for implementing the
EDCTP2 Programme and for receiving, allocating and monitoring the participating
states' contribution, as well as the Union’s financial contribution;

(c)
the demonstration by the EDCTP2-IS of its
capacity to implement the EDCTP2 Programme including receiving, allocating and
monitoring the Union’s contribution in the framework of indirect management of
the Union budget in accordance with Articles 58, 60 and 61 of Regulation (EU,
Euratom) No 966/2012;

(d)
the establishment of a governance model for the
EDCTP2 Programme in accordance with Annex III;

(e)
the commitment by each participating state to
contribute to the financing of the EDCTP2 Programme.

2.           During the implementation
of the EDCTP2 Programme, the Union financial contribution shall be conditional
upon the following:

(a)
the implementation by the EDCTP2-IS of the objectives
set out in Annex I and activities set out in Annex II to this Decision, in
particular the activities and indirect actions that it funds, in compliance
with Regulation (EU) No ... referred to in Article 6;

(b)
the maintenance of an appropriate and efficient
governance model for the EDCTP2 Programme in accordance with Annex III to this
Decision;

(c)
the compliance by the EDCTP2-IS with the
reporting requirements set out in Article 60(5) of Regulation (EU, Euratom) No
966/2012;

(d)
the fulfilment of the commitments referred to in
point (e) paragraph 1.

Article 4

Activities
of the EDCTP2 Programme

1.           The activities of the
EDCTP2 Programme shall meet the objectives described in Annex I to this Decision
and comply with Annex II.

Activities may include national programme activities
of participating states and new activities, including calls for proposals
managed by the EDCTP2-IS.

Activities shall be included in the work plan of
the EDCTP2 Programme adopted annually by the EDCTP2-IS following the positive
outcome of their external evaluation by international peer review based on Article
14(1) of Regulation (EU) No ... [Rules for the participation and dissemination in
Horizon 2020], and with regard to their contribution to the objectives of the
EDCTP2 Programme.

2.           The work plan shall detail
the budgeted value of each activity and provide for the allocation of the
funding managed by the EDCTP2-IS, including the Union contribution.

The work plan shall differentiate between the
activities funded or co-funded by the Union and those funded by participating
states or other revenues.

3.           The EDCTP2-IS shall implement
the annual work plan referred to in paragraph 1.

The EDCTP2-IS shall monitor and report to the
Commission on the implementation of all the activities included therein or
selected following calls for proposals managed by the EDCTP2-IS.

4.           Activities included in the
work plan that are not funded by the EDCTP2-IS shall be implemented in
compliance with common principles to be agreed by the participating states and
the Commission, taking into account the principles set out in this Decision, in
Title VI of Regulation (EU, Euratom) No 966/2012 and in Regulation (EU) No ... [Rules
for the participation and dissemination in Horizon 2020], in particular equal
treatment, transparency, independent peer review evaluation and selection. The
participating states and the Commission shall also agree on the reporting
requirements to the EDCTP2-IS, including with regard to indicators inserted
into each of these activities. 
Any activity funded by EDCTP2-IS in accordance with the work plan or following
calls for proposals managed by the EDCTP2-IS, shall be considered as an
indirect action under the meaning of Regulation (EU) No ... [Rules for the
participation and dissemination in Horizon 2020] and be implemented in
accordance with Article 6.

5.           Any communication or
publication related to activities of the EDCTP2 Programme, whether undertaken
by the EDCTP2-IS, a participating state, or participants to an activity, shall
be labelled or co-labelled as "[name of the activity] is part of the
EDCTP2 programme supported by the European Union".

Article 5

Contributions
from participating states

1.           Contributions from the participating
states shall consist of the following:

(a)
financial contributions to the EDCTP2-IS;

(b)
in kind contributions consisting of the costs
incurred by the participating states in implementing activities included in the
work plan referred to in Article 4(1) or in relation to the administrative budget
of the EDCTP2-IS.

2.           For the purpose of evaluating
the contributions referred to in point (b) of paragraph 1, the costs shall be
determined according to the usual accounting practices and accounting standards
of the participating state concerned and to the applicable International
Accounting Standards /International Financial Reporting Standards.

Article 6

Rules
for participation and dissemination

1.           Regulation (EU) No ...
[Rules for the participation and dissemination in Horizon 2020] shall apply to indirect
actions selected and funded by EDCTP-IS in accordance with the work plan
referred to in Article 4(1) or following calls for proposals managed by
EDCTP2-IS. In accordance with that Regulation, the EDCTP2-IS shall be
considered a funding body and shall provide financial support to indirect
actions in accordance with Annex II to this Decision.

2.           By derogation from Article
8(1)(b) of Regulation (EU) No ... [Rules for the participation and dissemination
in Horizon 2020], the minimum number of participants shall be two legal
entities established in two different participating states and a third legal
entity in a sub-Saharan African country listed in the EDCTP2 work plan referred
to in Article 4(1) of this Decision.

3.           By derogation from Article
9(1)(c) of Regulation (EU) No ... [Rules for the participation and dissemination
in Horizon 2020], any legal entity established in a sub-Saharan country listed in
the EDCTP2 work plan referred to in Article 4(1) of this Decision shall be
eligible for funding.

4.           Where such an activity is included
in the workplan, EDCTP2-IS may launch joint calls with third countries or their
scientific and technological organisations and agencies, with international
organisations or with other third parties, in particular non-governmental
organisations, in accordance with the rules developed based on Article 11 of
Regulation (EU) No ... [Rules for the participation and dissemination in Horizon
2020].

Article 7

Agreements
between the Union and the EDCTP2-IS

1.           Subject to a positive
ex-ante assessment of the EDCTP2-IS in accordance with Article 61(1) of
Regulation (EU, EURATOM) No 966/2012, the Commission, on behalf of the Union, shall conclude a delegation agreement and annual transfer of funds agreements with the
EDCTP2-IS.

2.           The delegation agreement
referred to in paragraph 1 shall be concluded in accordance with Articles 58(3),
60 and 61 of Regulation (EU, Euratom) No 966/2012 and Article 40 of Delegated Regulation
(EU) No 1268/2012. It shall also set out, inter alia, the following:

(a)
the requirements for the EDCTP2-IS contribution
regarding the performance indicators set out in Annex II to Decision (EU) No ...
[the Specific Programme implementing the Horizon 2020 Framework Programme];

(b)
the requirements for the EDCTP2-IS contribution in
relation to the monitoring referred to in Annex III to Decision (EU) No ... [the
Specific Programme implementing the Horizon 2020 Framework Programme];

(c)
the specific performance indicators related to
the functioning of the EDCTP2-IS;

(d)
the requirements for the EDCTP2-IS regarding the
provision of information on administrative costs and on detailed figures
concerning the implementation of the EDCTP2 Programme;

(e)
the arrangements regarding the provision of data
necessary to ensure that the Commission is able to meet its dissemination and
reporting obligations;

(f)
the modalities for approval or rejection by the
Commission of the draft annual work plan of the EDCTP2 Programme referred to in
Article 4(1), before it is adopted by the EDCTP2-IS.

Article 8

Termination,
reduction or suspension of the Union’s financial contribution

If the EDCTP2 Programme is not implemented
or is implemented inadequately, partially or late, the Commission may terminate,
proportionally reduce or suspend the Union’s financial contribution in line
with the actual implementation of the EDCTP2 Programme.

If the participating states do not
contribute, contribute partially or late to the financing of the EDCTP2
Programme, the Commission may terminate, proportionally reduce or suspend the Union’s financial contribution, taking into account the amount of funding allocated by the participating
states to implement the EDCTP2 Programme.

Article 9

Ex-post
audits

1.           Ex-post audits of
expenditure on indirect actions shall be carried out by EDCTP2-IS in accordance
with Article 23 of Regulation (EU) No ... [the Horizon 2020 Framework Programme]
.

2.           The Commission may decide
to carry out the audits referred to in paragraph 1 itself.

Article 10

Protection
of the financial interests of the Union

1.           The Commission shall take
appropriate measures ensuring that, when actions financed under this Decision
are implemented, the financial interests of the Union are protected by the
application of preventive measures against fraud, corruption and any other
illegal activities, by effective checks and, if irregularities are detected, by
the recovery of the amounts wrongly paid and, where appropriate, by effective,
proportionate and dissuasive administrative and financial penalties.

2.           The EDCTP2-IS shall grant
Commission staff and other persons authorised by it, as well as the Court of Auditors,
access to its sites and premises and to all the information, including
information in electronic format, needed in order to conduct their audits.

3.           The European Anti-fraud
Office (OLAF) may carry out investigations, including on-the-spot checks and
inspections, in accordance with Council Regulation (Euratom, EC) No 2185/96 [15] and Regulation (EC) No
1073/1999 of the European Parliament and of the Council[16] with a view to establishing
whether there has been fraud, corruption or any other illegal activity
affecting the financial interests of the Union in connection with an agreement
or decision or a contract funded in accordance with this Decision.

4.           Contracts, grant agreements
and grant decisions resulting from the implementation of this Decision shall
contain provisions expressly empowering the Commission, the EDCTP2-IS, the
Court of Auditors and OLAF to conduct such audits and investigations, according
to their competences.

5.           In implementing the EDCTP2
Programme, the participating states shall take the legislative, regulatory,
administrative and other measures necessary for protecting the Union’s
financial interests, in particular, to ensure full recovery of any amounts due
to the Union in accordance with Regulation (EU, Euratom) No 966/2012 and Delegated
Regulation (EU) No 1268/2012.

Article 11

Communication of information

1.           On request, the EDCTP2-IS
shall send any information necessary for preparation of the reports referred to
in Article 12 to the Commission.

2.           The participating states
shall submit to the Commission, through the EDCTP2-IS, any information that is requested
by the European Parliament, the Council or the Court of Auditors concerning the
financial management of the EDCTP2 Programme.

3.           The Commission shall include
the information referred to in paragraph 2 in the reports referred to in
Article 12.

Article 12

Evaluation

1.           By 31 December 2017 the
Commission shall conduct an interim evaluation of the EDCTP2 Programme. The
Commission shall prepare a report on that evaluation which includes conclusions
of the evaluation and observations by the Commission. The Commission shall send
that report to the European Parliament and to the Council by 30 June 2018.

2.           At the end of the Union
participation in EDCTP2 but not later than 31 December 2023, the Commission
shall conduct another interim evaluation of the EDCTP2 Programme. The
Commission shall prepare a report on that evaluation which includes the results
of that evaluation. The Commission shall send that report to the European
Parliament and the Council.

3.           The Commission shall
conduct a final evaluation of the EDCTP2 Programme by 31 December 2026. The
Commission shall send the results of that evaluation to the European Parliament
and the Council.

Article 13

Entry
into force

This Decision shall enter into force on the
twentieth day following that of its publication in the Official Journal of
the European Union.

Article 14

Addressees

This
Decision is addressed to the Member States.

Done at Brussels,

For the European Parliament                       For
the Council

The President                                                 The
President

ANNEX I
OBJECTIVES OF THE EDCTP2 PROGRAMME

EDCTP2 shall contribute to the following
objectives:

(1)
General Objective

EDCTP2 shall contribute to the reduction of the
social and economic burden of poverty-related diseases in developing countries,
in particular in sub-Saharan Africa, by accelerating the clinical development
of effective, safe and affordable medical interventions for poverty-related
diseases, in partnership with sub-Saharan Africa.

(2)
Specific Objectives

In order to contribute to the general objective,
EDCTP2 shall achieve the following specific objectives:

(a)
an increased number of new or improved medical
interventions for HIV/AIDS, tuberculosis, malaria and other poverty-related
diseases, and by the end of the programme to have delivered at least one new
medical intervention; to have issued at least 30 guidelines for improved or
extended use of existing medical interventions; and to have progressed the
clinical development of at least 20 candidate medical interventions;

(b)
strengthened cooperation with sub-Saharan
African countries, in particular on building their capacity for conducting
clinical trials in compliance with fundamental ethical principles and relevant
national, Union and international legislation, including the Charter of
Fundamental Rights of the European Union, the European Convention on Human
Rights and its Supplementary Protocols, the World Medical Association’s
Declaration of Helsinki of 2008 and the standards on good clinical practice adopted
by the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH);

(c)
better coordination, alignment and integration
of relevant national programmes to increase the cost-effectiveness of European
public investments;

(d)
extended international cooperation with other
public and private funders;

(e)
an increased impact due to effective cooperation
with relevant European Union initiatives, including its development assistance.

(3)
Operational Objectives

In order to reach the
specific objectives set out in point 2, the following operational objectives,
including indicative targets, shall be met by the end of the EDCTP2 programme in
2024:

(a)
Support clinical trials on new or improved
medical interventions for poverty-related diseases through partnerships between
European and developing countries, in particular sub-Saharan Africa:

Target: increase the number of supported
clinical trials to at least 150 compared to 88 under EDCTP1.

Target: sustain or increase the proportion of
clinical trials funded by the EDCTP2-IS with African leadership to at least 50 %.

Target: Increase the number of peer-reviewed
scientific articles published to at least 1000.

(b)
Support research capacity-building activities in
sub-Saharan Africa enabling clinical trials to be conducted and helping to
reduce the brain drain:

Target: sustain or increase the number of
sub-Saharan African countries supported by the EDCTP2 to at least 30.

Target: increase the number of fellowships to sub-Saharan
African researchers and MSc/PhD students to at least 600 compared to 400 under EDCTP1,
with at least 90 % of them continuing their research career in sub-Sahara Africa for at least one year after their fellowship.

Target: increase the number of capacity-building
activities supported for conducting clinical trials in sub-Saharan Africa to at least 150 compared to 74 under EDCTP1.

(c)
Develop a common research agenda, criteria for
priority setting and common evaluation:

Target: at least 50 % of the public
investment by participating European states are integrated, aligned or
coordinated through the EDCTP2 Programme.

(d)
Ensure efficiency of the implementation of the EDCTP2
Programme:

Target: administrative costs are below 5 %
of the EDCTP2-IS budget.

(e)
Establish cooperation and launch joint actions with
other public and private funders.

Target: increase the contributions received
from developing countries to at least EUR 30 million compared to EUR 14
million under EDCTP1.

Target: obtain additional contributions, either
public or private, of at least EUR 500 million compared to EUR 71
million under EDCTP1.

(f)
Establish cooperation and launch joint actions
with Union, national and international development assistance initiatives in
order to ensure complementarity and increase the impact of the results of EDCTP-funded
activities.

ANNEX II
ACTIVITIES AND IMPLEMENTATION OF THE EDCTP2 PROGRAMME

(1)
Activities

The EDCTP2 Programme shall include the
following activities:

(a)
promoting networking, coordination, alignment,
cooperation and integration of national research programmes and activities on
poverty-related infectious diseases at scientific, management and financial
level;

(b)
supporting clinical trial research and related
activities on poverty-related diseases, in particular HIV/AIDS, malaria,
tuberculosis and neglected infectious diseases;

(c)
fostering capacity development for clinical
trials and related research in developing countries through grants for: career
development of junior/senior fellows, promoting mobility, staff exchange
grants, research training networks, strengthening ethics and regulatory bodies,
mentoring and partnerships at individual or institutional level;

(d)
establishing cooperation and launching joint
actions with other public and private funders;

(e)
assuring awareness, endorsement and
acknowledgment of the EDCTP2 Programme and its activities through advocacy and
communication.

(2)
Programme definition and implementation

The EDCTP2 Programme shall be implemented by the
EDCTP2-IS on the basis of an annual work plan and a multiannual strategic work
plan prepared by the EDCTP2-IS and adopted by the General Assembly of the EDCTP2-IS
following international peer-review and subject to the prior approval by the Commission.

The annual work plan shall identify topics and activities
to be implemented, including calls for proposals to be launched by EDCTP-IS to select
and fund indirect actions, as well as the budgets and EDCTP2 funding for those
topics and activities.

The annual work plan shall differentiate
between the activities funded or co-funded by the Union and those funded by
participating states or other revenues.

The multiannual strategic work plan shall set a
common strategic research agenda which shall be prepared and updated on an
annual basis.

EDCTP2-IS shall monitor the implementation of
the activities included in the workplan, including indirect actions selected
through calls for proposals it manages. It shall allocate and manage funding to
these in accordance with this Decision and the effective implementation of
activities selected and identified in the previous workplans.

(3)
Deliverables expected from the implementation of
the EDCTP2 Programme

An annual report shall be provided by
EDCTP2-IS, which shall give a detailed overview of the implementation of the EDCTP2
Programme. That overview shall provide information on each activity selected in
accordance with the work plan, including indirect actions selected through
calls for proposals managed by EDCTP-IS. Such information shall include a
description of each activity, including indirect action, its budget, the value
of the funding allocated to it if any, and its status.

With regards to calls managed by EDCTP-IS, the
annual report shall moreover include information on the number of projects
submitted and selected for funding, the detailed use of the Union financial
contribution, the distribution of national and other contributions, the types
of participants, country statistics, brokerage events and dissemination
activities.

The annual report shall also include
information on the progress towards achieving the EDCTP2 Programme objectives
set out in Annex I.

In addition, the EDCTP2-IS shall provide any
report and information foreseen by this Decision and the agreement concluded
with the Union.

ANNEX III
GOVERNANCE OF THE EDCTP2 PROGRAMME

The organisational structure of the EDCTP2
Programme shall comprise the following:

(1)
The EDCTP2-IS shall be governed by a general
assembly (hereinafter ''GA''), in which all participating states are
represented.

The GA’s principal responsibility shall be to
ensure that all necessary activities are undertaken to achieve the objectives
of the EDCTP2 Programme, and that its resources are properly and efficiently
managed. It shall adopt the annual work plan.

The GA shall decide by consensus. Failing
consensus, the GA shall take its decisions by a majority of at least 75 %
of the votes.

The Union, represented by the Commission, shall
be invited to all GA meetings as an observer, and shall receive all necessary
documents. It may take part in discussions.

(2)
The GA shall appoint a management board that
shall supervise the secretariat of the EDCTP2-IS (hereinafter ''SEC'') established
by the GA as the executive body of the EDCTP2 Programme.

SEC shall have the following tasks:

(a)
represent the EDCTP2-IS;

(b)
provide support to the GA;

(c)
implement the EDCTP2 Programme and manage those
of its activities entrusted to EDCTP2-IS by the annual work plan

(d)
monitor and report on the implementation of the EDCTP2
Programme;

(e)
manage the financial contributions from the participating
states, the Union and any third party, and report on their use to the GA and
the Union;

(f)
increase the visibility of the EDCTP2 Programme
through advocacy and communication;

(g)
liaise with the Commission in accordance with
the delegation agreement referred to in Article 7.

(3)
A Scientific Advisory Committee (hereinafter ‘SAC’)
shall advise the GA on the strategic priorities of the EDCTP2 Programme.

The SAC shall be appointed by the GA and consist
of European and African independent experts competent in areas relevant to the EDCTP2
Programme.

The SAC shall have the following tasks:

(a)
advise the GA on priorities and strategic needs
regarding clinical trials in Africa

(b)
review and advise the GA on the content, scope
and dimension of the EDCTP2 draft annual work plan, including diseases covered
and approaches to be adopted, from a scientific and technical standpoint

(c)
review the scientific and technical aspects of
the implementation of the EDCTP2 Programme and deliver an opinion on its annual
report

In exercising its tasks, the SAC shall monitor
and promote high standards of ethical conduct of clinical trials and engage
with vaccine regulatory authorities.

The SAC may recommend to the GA the setting up of
scientific subcommittees, task forces and working groups.

The GA shall establish the number of SAC
members, their voting rights and the modalities of their appointment in
accordance with Article 37 of Regulation (EU) No ... [Rules for the participation
and dissemination in Horizon 2020]. The GA may set up specialised working
groups under the SAC with additional independent experts for specific tasks.

LEGISLATIVE FINANCIAL STATEMENT

1.           FRAMEWORK OF THE PROPOSAL/INITIATIVE

1.1.    Title of the proposal/initiative

1.2.    Policy
area(s) concerned in the ABM/ABB structure

1.3.    Nature
of the proposal/initiative

1.4.    Objectives

1.5.    Grounds
for the proposal/initiative

1.6.    Duration
and financial impact

1.7.    Management
mode(s) envisaged

2.           MANAGEMENT MEASURES

2.1.    Monitoring
and reporting rules

2.2.    Management
and control system

2.3.    Measures
to prevent fraud and irregularities

3.           ESTIMATED FINANCIAL IMPACT OF THE
PROPOSAL/INITIATIVE

3.1.    Heading(s)
of the multiannual financial framework and expenditure budget line(s) affected

3.2.    Estimated
impact on expenditure

3.2.1. Summary of
estimated impact on expenditure

3.2.2. Estimated impact
on operational appropriations

3.2.3. Estimated impact
on appropriations of an administrative nature

3.2.4. Compatibility
with the current multiannual financial framework

3.2.5. Third-party
contributions

3.3.    Estimated impact on revenue

LEGISLATIVE FINANCIAL STATEMENT

1.           FRAMEWORK OF THE PROPOSAL/INITIATIVE

1.1.        Title of the
proposal/initiative

Decision of the European Parliament and of the Council on the
participation of the European Union in a second European and Developing
Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by
several Member States

1.2.        Policy area(s) concerned
in the ABM/ABB structure[17]

Title 08 Research and Innovation, Horizon 2020 Framework Programme

1.3.        Nature of the
proposal/initiative

 ̈ The proposal/initiative relates to a new action

 ̈ The proposal/initiative relates to a new action
following a pilot project/preparatory action[18]

 ̈ The proposal/initiative relates to the extension of
an existing action

ý The proposal/initiative relates to an action
redirected towards a new action

1.4.        Objectives

1.4.1.     The Commission’s
multiannual strategic objective(s) targeted by the proposal/initiative

EDCTP2 will contribute to the Europe 2020 strategy and the
completion of the European Research Area, including the target of 3 % of
the EU’s GDP to be invested in R&D, by developing a real partnership with
developing countries to help eradicate poverty, promote growth and contribute
to the Millennium Development Goals.

1.4.2.     Specific objective(s) and
ABM/ABB activity(ies) concerned

EDCTP2 implementation: EDCTP2 will contribute to reducing the social
and economic burden of poverty-related diseases (PRDs) in developing countries,
in particular in sub-Saharan Africa, by accelerating the clinical development
of effective, safe and affordable medical interventions for PRDs in partnership
with sub-Saharan Africa.

ABM/ABB activity concerned: 08.02
Cooperation — Health

1.4.3.     Expected result(s) and
impact

Specify the effects
which the proposal/initiative should have on the beneficiaries/groups targeted.

1) More of new or
improved medical interventions for HIV/AIDS, tuberculosis, malaria and other
poverty-related diseases for the benefit of developing countries, and by the
end of the programme to have delivered at least 1 new medical intervention; to
have issued at least 20 guidelines for improved or extended use of existing
medical interventions; and to have progressed the clinical development of at
least 10 candidate medical intervention.

2) Strengthened
cooperation with sub-Saharan African countries, in particular on building their
capacity for conducting clinical trials.

3) Better
coordination, alignment and integration of relevant national programmes to
increase the cost-effectiveness of European public investment.

4) Extended
international cooperation with other public and private funders.

5) An increased
impact due to effective cooperation with other Union initiatives, including EU
development assistance.

1.4.4.     Indicators of results and
impact

Specify the
indicators for monitoring implementation of the proposal/initiative.

- Number of clinical
trial results integrated in guidelines or recommendations for improved clinical
practice or submitted to regulators.

- Proportion of
public investments of participating European states that are integrated,
aligned or coordinated through the EDCTP joint programme.

- Number of African
countries involved in EDCTP-funded projects.

- Share of
EDCTP-funded clinical trials with African leadership.

- Number of medical
interventions proceeding to further development (through additional trials or
next phase).

- Number of joint
peer-reviewed scientific articles.

- Number of African
researchers supported by EDCTP fellowships staying on in Africa at least one
year after the end of their training.

- Number of clinical
trials supported.

- Number of capacity-building
activities supported for conducting clinical trials in sub-Saharan Africa.

- Number of
fellowships to African researchers and MSc/PhD students.

- Time-to-grant and
Time-to-pay.

- Volume and proportion
of co-funding from the Union and the PSs, including funds raised by the PSs and
the EDCTP from other public and private third parties.

- Administrative
costs.

1.5.        Grounds for the
proposal/initiative

1.5.1.     Requirement(s) to be met in
the short or long term

Despite the promising results of EDCTP1 and other international
initiatives, there is still a lack of effective medical interventions for PRDs.
The socio-economic burden of these diseases remains a limiting factor for the
sustainable development of developing countries, in particular in sub-Saharan Africa. While a general improvement in factors such as nutrition, sanitation and
infrastructure is certainly important, the development of new and better
medical interventions is essential for an effective containment and long-term
control of PRDs.

The persistent lack of effective medical interventions for PRDs is
affected by five key drivers that require Union intervention through EDCTP2:
insufficient investment; weak clinical research capacity in sub-Saharan African
countries; fragmented public support; the limited scope of the EDCTP1
programme; and insufficient links to other EU initiatives. First and foremost,
the medical interventions needed for PRDs will not be developed by the private
sector alone owing to limited financial incentives (market failure). Second,
clinical trials are of such scale and complexity that no single country can
provide the necessary resources. The EU-level approach on which EDCTP is built makes
it possible to achieve the necessary critical mass of resources, with Union funding complementing participating states’ contributions to EDCTP2.

For more information, please read the impact assessment report of
EDCTP2 accompanying this legislative proposal.

1.5.2.     Added value of EU
involvement

Public intervention at EU level is necessary to bring together
compartmentalised national research programmes, help design common research and
funding strategies across national borders and achieve the critical mass of
actors and investment needed for undertaking resource-intensive clinical trials
of new medical interventions for poverty-related diseases in developing
countries. In doing so, the impact of European activities and effectiveness of
public investment in this field is maximised. In light of budgetary restrictions
and from a purely economic perspective, it makes more sense than ever to invest
collectively in order to maximise the cost-effectiveness and impact. Public intervention
is in line with the overall provisions of the EU Treaty, related EU policies
and, in particular, contributes to delivering on the Union’s commitments to
promote aid effectiveness, inclusive growth and progress towards achieving the
Millennium Development Goals.

1.5.3.     Lessons learned from
similar experiences in the past

Up until now, EDCTP
has funded 241 projects involving 185 African and 70 European research
institutions. This includes 88 clinical trials which were all subject to
ethical clearance from the competent national ethics board(s) in the country or
countries in which the trial(s) were due to take place before any funding was granted
by EDCTP. Most of the clinical trials supported by EDCTP were launched after
2007 and are still on-going. Nevertheless, they have already generated more
than 350 scientific publications in peer-reviewed journals, while the results of
eight clinical trials so far have been integrated in guidelines for improved
clinical practice.

Despite these
achievements, a number of issues were raised in the 2009 interim evaluation
report and the public consultation. These following issues are fundamental to the
design and subsequent implementation of EDCTP2:

- the current scope
of EDCTP needs to be changed and extended;

- the integration of
European national programmes should be further improved;

- collaboration with
other major public and private funders, including the pharmaceutical industry,
needs to be strengthened and extended;

- synergies with European
external policy actions should be developed, in particular with EU development
assistance;

- co-funding rules
should be clarified and simplified;

- monitoring tools
need to be strengthened.

For more information,
please read the impact assessment report of EDCTP2 accompanying this
legislative proposal.

1.5.4.     Compatibility and possible
synergy with other appropriate instruments

EDCTP was conceived to complement the actions implemented under the
European Development Fund (EDF) and the Development Cooperation Instrument
(DCI) to ensure the development and delivery of medical interventions to those
in need. So far, interaction with these European programmes for development
assistance has been limited, but the opportunity remains to better exploit
synergies and achieve greater impact of Union actions in research and
development assistance. The remit of EDCTP is restricted to support clinical
trials and corresponding capacity-building. However, in resource-poor settings
like sub-Saharan Africa, such activities do not exist in isolation, and would
achieve a far greater impact if they were integrated in and coordinated with
national healthcare systems and programmes.

For more information, please read the impact assessment report of
EDCTP2 accompanying this legislative proposal.

1.6.        Duration and financial
impact

ý Proposal/initiative of limited
duration

–
ý  Proposal/initiative in effect from 1/1/2014 to 31/12/2024

–
ý  Financial impact from 2014 to 2020 for commitment appropriations
and from 2014 to 2024 for payment appropriations

 ̈ Proposal/initiative of unlimited
duration

–
Implementation with a start-up period from YYYY
to YYYY,

–
followed by full-scale operation.

1.7.        Management mode(s)
envisaged[19]

 ̈ Centralised direct management by the Commission

ý Centralised indirect management with the delegation of implementation tasks to:

–
 ̈  executive agencies

–
 ̈  bodies set up by the Communities[20]

–
ý  national public-sector bodies/bodies with public-service mission

–
 ̈  persons entrusted with the implementation of specific actions
pursuant to Title V of the Treaty on European Union and identified in the
relevant basic act within the meaning of Article 49 of the Financial Regulation

 ̈ Shared management with the Member States

 ̈ Decentralised management with third countries

 ̈ Joint management with international organisations (to be specified)

If more than one
management mode is indicated, please provide details in the ‘Comments’ section.

Comments

EDCTP2 shall
be implemented through the EDCTP legal entity as the implementation structure
(EDCTP2-IS). The current EDCTP legal entity was established by the 15 European
founding countries as a European Economic Interest Group (EEIG) in the Netherlands. A new EDCTP legal entity will be established before the launch of the EDCTP2
Programme, based on organisational principles detailed in Annex III.

2.           MANAGEMENT MEASURES

2.1.        Monitoring and reporting
rules

Specify frequency
and conditions.

Implementation of EDCTP2 will be monitored through annual reports
covering a single year N, which will be provided by the EDCTP-IS in year N+1.
These annual reports will give a detailed overview of EDCTP2 activities in year
N in comparison to the multiannual strategic work plan (covering year N to year
N+2) and the annual work plan of year N. They will also provide detailed
information on the performance and progress towards meeting EDCTP2 objectives and
targets. These annual reports will also include updated figures on the
indicators listed in section 1.4.4.

An interim evaluation will be carried out with the assistance of
independent external experts after three years of operation but not later than
31 December 2017.

Before the end of EDCTP2 but not later than 31 December 2023, the
Commission will conduct another interim evaluation with the assistance of
independent external experts.

A final independent ex-post evaluation after EDCTP2 has ended but
not later than 31 December 2026 will be conducted by an independent expert
panel set up by the Commission and tasked with reviewing the performance and
quality of EDCTP2 implementation and funded activities.

2.2.        Management and control
system

2.2.1.     Risk(s) identified

1) The main risk concerns the capacity of participating states to
effectively integrate their national programmes and activities, and thus
deliver their contribution to the programme.

2) A second risk concerns effective protection against fraud and
possible financial losses, especially due to weak governance and financial
capacity in some of the developing countries and the corresponding
beneficiaries of EDCTP2 grants.

3) A third risk concerns the capacity of the implementation
structure to manage the Unions budget contribution and monitor the national
activities contributing to the programme.

4) A fourth risk relates to the high costs, long duration, ethical
clearance and regulatory control required for clinical trials in humans, which
can result in clinical trials lasting longer than initially planned and/or
being more costly. This is often linked to delays in ethical clearance and/or to
clinical findings that require modification of clinical trials design.

2.2.2.     Control method(s) envisaged

The Union’s financial interests will be protected through
proportionate measures throughout the expenditure life-cycle, including the
prevention, detection and investigation of irregularities, the recovery of
funds lost, wrongly paid or incorrectly used and, where appropriate, penalties.

Article 8 states that if EDCTP2 is not implemented or is implemented
inadequately, partially or late, or if the Participating States do not
contribute, contribute partially or late to the financing of EDCTP2, the
Commission may reduce, withhold or terminate the European Union financial
contribution.

Articles 9 and 10 set out the EDCTP-IS' duty to guarantee a level of
protection of the financial interests of the Union and makes provision for
access to information and premises to control, evaluate and carry out audits on
EDCTP2 implementation.

2.2.3.     Costs and benefits of
controls and probable non-compliance rate

Article 9 provides for ex-post audits of expenditure on indirect
actions to be carried out in accordance with the Horizon 2020 Framework
Programme. To ensure consistency, the Commission may decide to carry out the
audits referred to in herein.

2.3.        Measures to prevent fraud
and irregularities

Specify existing or
envisaged prevention and protection measures.

Article 10 sets out that the EDCTP-IS has to grant access to
information and premises necessary for the Commission to control, evaluate and
carry out audits on EDCTP2 implementation or for OLAF to carry out
investigations.

3.           ESTIMATED FINANCIAL IMPACT OF THE
PROPOSAL/INITIATIVE

3.1.        Heading(s) of the
multiannual financial framework and expenditure budget line(s) affected

· Existing budget lines

In order of
multiannual financial framework headings and budget lines.

Heading of multiannual financial framework || Budget line || Type of expenditure || Contribution

Heading la - Competitiveness for growth and jobs || Diff./non-diff. ([21]) || from EFTA countries[22] || from candidate countries[23] || from third countries || within the meaning of Article 18(1)(aa) of the Financial Regulation

|| Administrative Expenditures 08.01.05.03 Other management expenditure for Research || NDA || YES || YES || YES || YES

|| Operational Expenditures Societal challenges 08.02.03.01 Improving lifelong health and wellbeing || DA || YES || YES || YES || YES

· New budget lines requested

In order of multiannual financial framework
headings and budget lines.

Heading of multiannual financial framework || Budget line || Type of expenditure || Contribution

Heading la - Competitiveness for growth and jobs || Diff./non-diff. || from EFTA countries || from candidate countries || from third countries || within the meaning of Article 18(1)(aa) of the Financial Regulation

|| Administrative Expenditures 08.01.05.03 Other management expenditure for Research || NDA || YES || YES || YES || YES

|| Operational Expenditures Societal challenges 08.02.03.01 Improving lifelong health and wellbeing || DA || YES || YES || YES || YES

3.2.        Estimated impact on
expenditure

3.2.1.     Summary of estimated impact
on expenditure

EUR million (to three decimal places)

Heading of multiannual financial framework: || 1A || Heading la - Competitiveness for growth and jobs

DG: RTD || || || Year 2014 || Year 2015 || Year 2016 || Year 2017 || Year 2018 || Year 2019 || Year 2020 || Years 2021-2024 || TOTAL

Ÿ Operational appropriations || || || || || || || || ||

08.02.03.01 || Commitments || (1) || 25,000 || 55,000 || 80,000 || 110,000 || 110,000 || 110,000 || 193,000 || 0,000 || 683,000

Payments || (2) || 4,000 || 20,000 || 50,000 || 110,000 || 110,000 || 130,000 || 130,000 || 129,000 || 683,000

Ÿ Appropriations of an administrative nature financed from the envelope of specific programmes[24] || || || || || || || || ||

08.01.05.03 || || (3) || 0,297 || 0,303 || 0,309 || 0,315 || 0,321 || 0,328 || 0,334 || 0,000 || 2,207

TOTAL appropriations under HEADING 1A of the multiannual financial framework || Commitments || =4+6 || 25,297 || 55,303 || 80,309 || 110,315 || 110,321 || 110,328 || 193,334 || 0,000 || 685,207

Payments || =5+6 || 4,297 || 20,303 || 50,309 || 110,315 || 110,321 || 130,328 || 130,334 || 129,000 || 685,207

Heading of multiannual financial framework || 1A || Heading la - Competitiveness for growth and jobs ‘Administrative expenditure’

EUR million (to three decimal places)

|| || || Year 2014 || Year 2015 || Year 2016 || Year 2017 || Year 2018 || Year 2019 || Year 2020 || Years 2021-2024 || TOTAL

DG: RTD || ||

Ÿ Human resources || 0,297 || 0,303 || 0,309 || 0,315 || 0,321 || 0,328 || 0,334 || 0,000 || 2,207

Ÿ Other administrative expenditure || 0,000 || 0,000 || 0,000 || 0,000 || 0,000 || 0,000 || 0,000 || 0,000 || 0,000

TOTAL DG RTD || || 0,297 || 0,303 || 0,309 || 0,315 || 0,321 || 0,328 || 0,334 || 0,000 || 2,207

TOTAL appropriations for HEADING 1A of the multiannual financial framework || (Total commitments = Total payments) || 0,297 || 0,303 || 0,309 || 0,315 || 0,321 || 0,328 || 0,334 || 0,000 || 2,207

EUR million (to three decimal places)

|| || || Year 2014 || Year 2015 || Year 2016 || Year 2017 || Year 2018 || Year 2019 || Year 2020 || Years 2021-2024 || TOTAL

TOTAL appropriations under HEADINGS 1 to 5 of the multiannual financial framework || Commitments || 25,297 || 55,303 || 80,309 || 110,315 || 110,321 || 110,328 || 193,334 || 0,000 || 685,207

Payments || 4,297 || 20,303 || 50,309 || 110,315 || 110,321 || 130,328 || 130,334 || 129,000 || 685,207

3.2.2.     Estimated impact on
operational appropriations

–
 ̈  The proposal/initiative does not require the use of operational
appropriations

–
ý  The proposal/initiative requires the use of operational
appropriations, as explained below:

Commitment appropriations in EUR million (to three
decimal places)

Indicate objectives and outputs * ò || || || Year 2014 || Year 2015 || Year 2016 || Year 2017 || Year 2018 || Year 2019 || Year 2020 || TOTAL

OUTPUTS

Type[25] || Average cost ** || Number || Cost || Number || Cost || Number || Cost || Number || Cost || Number || Cost || Number || Cost || Number || Cost || Total Number || Total Cost

SPECIFIC OBJECTIVE No 1 || EDCTP2 implementation

- Output || R&D activity || 1,442 || 87 || 126,060 || 104 || 149,826 || 116 || 166,798 || 135 || 194,999 || 131 || 188,759 || 129 || 186,695 || 198 || 284,923 || 900 || 1.298,060

- Output || || || || || || || || || || || || || || || || || ||

Subtotal for specific objective No 1 || || || || || || || || || || || || || || || ||

TOTAL COST || 87 || 126,060 || 104 || 149,826 || 116 || 166,798 || 135 || 194,999 || 131 || 188,759 || 129 || 186,695 || 198 || 284,923 || 900 || 1.298,060

- Provided
that the PS contribution is increased by at least 15% through new Participating
Countries joining EDCTP2 as provided in Article 2.1, such that the total value
of the EDCTP2 programme is at least EUR1.366,379 million, including up to 5%
(EUR 68,319 million) for administrative costs, with an EU contribution of EUR 683,000
million (out of which 6% equal to EUR 41 million for administrative costs).

** An average cost per R&D activity was calculated
on the basis of the operational targets for the minimum number of specific
R&D activities to be supported by the EDCTP2 programme and estimated
average costs per specific R&D activity: 150 clinical trials (€7,254
million); 600 fellowships (€0,200 million); 150 capacity strengthening
activities (€0,600 million)

3.2.3.     Estimated impact on
appropriations of an administrative nature

3.2.3.1.  Summary

–
 ̈  The proposal/initiative does not require the use of appropriations
of an administrative nature

–
ý  The proposal/initiative requires the use of appropriations of an
administrative nature, as explained below:

EUR million (to
three decimal places)

|| Year 2014 || Year 2015 || Year 2016 || Year 2017 || Year 2018 || Year 2019 || Year 2020 || TOTAL

HEADING 5A of the multiannual financial framework || || || || || || || ||

Outside HEADING 5A of the multiannual financial framework || || || || || || || ||

Human resources || 0,297 || 0,303 || 0,309 || 0,315 || 0,321 || 0,328 || 0,334 || 2,207

Other expenditure of an administrative nature || || || || || || || ||

Subtotal outside HEADING 5A of the multiannual financial framework || 0,297 || 0,303 || 0,309 || 0,315 || 0,321 || 0,328 || 0,334 || 2,207

TOTAL || 0,297 || 0,303 || 0,309 || 0,315 || 0,321 || 0,328 || 0,334 || 2,207

The administrative
appropriations required will be met by the appropriations of the DG which are
already assigned to management of the action and/or which have been redeployed
within the DG, together if necessary with any additional allocation which may be
granted to the managing DG under the annual allocation procedure and in the
light of budgetary constraints.

3.2.3.2.  Estimated requirements of
human resources

–
 ̈  The proposal/initiative does not require the use of human
resources.

–
ý  The proposal/initiative requires the use of human resources, as
explained below:[26]

Estimate to be expressed in full time
equivalent units

|| Year 2014 || Year 2015 || Year 2016 || Year 2017 || Year 2018 || Year 2019 || Year 2020

|| Ÿ Establishment plan posts (officials and temporary agents)

08 01 01 01 (Headquarters and Commission’s Representation Offices) || || || || || || ||

08 01 01 02 (Delegations) || || || || || || ||

08 01 05 01 (Indirect research) || 2 || 2 || 2 || 2 || 2 || 2 || 2

10 01 05 01 (Direct research) || || || || || || ||

|| Ÿ External personnel (in Full Time Equivalent unit: FTE)[27]

XX 01 02 01 (CA, INT, SNE from the ‘global envelope’) || || || || || || ||

XX 01 02 02 (CA, INT, JED, LA and SNE in the delegations) || || || || || || ||

XX 01 04 yy[28] || - at headquarters || || || || || || ||

- in delegations || || || || || || ||

08 01 05 02 (CA, SNE, INT — Indirect research) || 0.5 || 0.5 || 0.5 || 0.5 || 0.5 || 0.5 || 0.5

10 01 05 02 (CA, SNE, INT — Direct research) || || || || || || ||

Other budget lines (specify) || || || || || || ||

TOTAL || 2.5 || 2.5 || 2.5 || 2.5 || 2.5 || 2.5 || 2.5

XX is the policy area or budget title
concerned.

The human resources
required will be met by staff from the DG who are already assigned to
management of the action and/or have been redeployed within the DG, together if
necessary with any additional allocation which may be granted to the managing
DG under the annual allocation procedure and in the light of budgetary
constraints.

Description of
tasks to be carried out:

Officials and temporary staff || Participation in EDCTP General Assembly: 2 two-day meetings/year (Director, Head of Unit). Participation in EDCTP Scientific Advisory Committee: 2 two-day meetings/year (Head of Unit, project officer). Participation in stakeholder consultation and information events: 8 events per year (Head of Unit, project officer). Negotiation, preparation and payment of delegation agreement with the EDCTP-IS (project officer, financial officer, administrative assistant). Monitoring of EDCTP2, assistance to interim/final evaluations (project officer). Financial and legal auditing of EDCTP2 (financial officer).

External staff || Monitoring of EDCTP2, assistance to interim/final evaluations (contract agent)

3.2.4.     Compatibility with the
current multiannual financial framework

–
ý  Proposal/initiative is compatible with the current multiannual
financial framework.

–
 ̈  Proposal/initiative will entail reprogramming of the relevant
heading in the multiannual financial framework.

Explain what reprogramming is required,
specifying the budget lines concerned and the corresponding amounts.

–
 ̈  Proposal/initiative requires application of the flexibility
instrument or revision of the multiannual financial framework[29].

Explain what is required, specifying the
headings and budget lines concerned and the corresponding amounts.

3.2.5.     Third-party contributions

–
The proposal/initiative does not provide for
co-financing by third parties.

–
ýThe proposal/initiative provides for the co-financing estimated
below:

Appropriations in EUR million (to three decimal
places)

|| 2014 || 2015 || 2016 || 2017 || 2018 || 2019 || 2020 || Total

Commitments of EDCTP2 Participating States* as listed in Article 1 || 106,833 || 102,216 || 77,616 || 77,616 || 71,116 || 68.966 || 90,016 || 594,379

Commitments of any other Member State or any other country associated to Horizon 2020 joining the EDCTP2 Programme in accordance with Article 2 || 0,000 || 0,000 || 17,800 || 17,800 || 17,800 || 17,800 || 17,800 || 89,000

TOTAL appropriations co-financed || 106,833 || 102,216 || 95,416 || 95,416 || 88,916 || 86,766 || 107,816 || 683,379

- EDCTP2
Participating States' (PS) commitments as endorsed by the EDCTP General
Assembly of PS representatives and communicated to the Commission in June 2013.
Accordingly, an updated EDCTP2 Strategic Business Plan will be published by
EDCTP:
http://www.edctp.org/Towards_EDCTP2.799.0.html

Co-Financing
details:

The Participating
States' contributions shall be at least equal to the EU contribution. The EU
contribution shall in any case not exceed EUR 683,000 million.

Up to 5% of the total
value of the EDCTP2 programme will be for administrative costs of the EDCTP2-IS,
up to a maximum of EUR 68,319 million. The maximum EU contribution to these administrative
costs will be up to 6% of the EU contribution to EDCTP2, thus not exceeding EUR
41,000 million.

[1]               The amount is indicative and will depend on the final
amount for the DG Research & Innovation under the above-mentioned
challenge.

[2]               OJ C ...[ESC opinion].

[3]               COM(2010)2020 final of 3.3.2010.

[4]               OJ... [Horizon 2020 Framework Programme].

[5]               OJ L 169 of 8.7.2003, p. 1-5.

[6]               OJ L 232 of 29.8.2002, p. 1-33.

[7]               OJ L 412 of 30.12.2006, p. 1-43.

[8]               Van Velzen et al., Independent External Evaluation
Report, December 2009.

[9]               OJ L ... [Horizon 2020 Specific Programme].

[10]             COM(2010)128 final.

[11]             COM(2011) 572 final.

[12]             OJ L 298 of 26.10.2012, p. 1-96.

[13]             OJ L 362 of 31.12.2012, p. 1-111.

[14]             OJ [H2020 RfP].

[15]             OJ L 292, 15.11.1996, p. 2-5.

[16]             OJ L 136,
31.5.1999, p. 1–7.

[17]             ABM: Activity-Based Management — ABB: Activity-Based
Budgeting.

[18]             As referred to in Article 49(6)(a) or (b) of the Financial Regulation.

[19]             Details of management modes and references to the
Financial Regulation may be found on the BudgWeb site: http://www.cc.cec/budg/man/budgmanag/budgmanag_en.html.

[20]             As referred to in Article 185 of the Financial Regulation.

[21]             Diff. = Differentiated appropriations / Non-Diff. = Non-differentiated
appropriations.

[22]             EFTA: European Free Trade Association. .

[23]             Candidate countries and, where applicable, potential
candidate countries from the Western Balkans.

[24]             Technical and/or administrative
assistance and expenditure in support of the implementation of EU programmes
and/or actions (former ‘BA’ lines), indirect research, direct research.

[25]             Outputs are products and
services to be supplied (e.g.: number of student exchanges financed, number of
km of roads built, etc.).

[26]             Staff needed after 2020 for follow-up of EDCTP2
implementation will be determined at a later stage.

[27]             CA= Contract Agent; LA = Local
Agent; SNE = Seconded National Expert; INT = agency staff (‘Intérimaire’); JED= ‘Jeune Expert
en Délégation’ (Young Experts
in Delegations).

[28]             Sub-ceiling
for external staff covered by
operational appropriations (former ‘BA’ lines).

[29]             See points 19 and 24 of the Interinstitutional
Agreement.